D. Decaudin et al., Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study, BONE MAR TR, 25(3), 2000, pp. 251-256
Citations number
28
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
This study was designed to evaluate the efficacy of therapeutic intensifica
tion with autologous stem cell transplantation (ASCT) for mantle cell lymph
omas (MCL) in terms of response rate, duration of response, and event-free
and overall survivals. Twenty-four patients with confirmed MCL responding t
o chemotherapy received a high-dose chemo-radiotherapy regimen followed by
ASCT, Transplantation was performed during first-line therapy in nine cases
, second-line in 13 cases and third-line in two cases. The source of hemato
poietic stem cells was peripheral blood for 19 cases. At the time of ASCT,
eight patients were in complete remission (33%). Seventeen of the 24 cases
received an intensified regimen with TBI and seven received the BEAM or the
BEAC regimen, After transplantation, 19 patients were in CR (79%). Nine of
these were alive in continued CR at a median follow-up of 34 months, while
seven relapsed at a median of 18 months. One patient died from Pneumocysti
s carinii interstitial pneumonitis and five patients developed secondary ma
lignancies. With a median follow-up after transplantation of 34 months, the
3-year event-free survival was 55% and the 3-year overall survival was 68%
. These results indicate that therapeutic intensification with ASCT might b
e an effective treatment for mantle cell lymphomas.